JP2024521131A5 - - Google Patents
Info
- Publication number
- JP2024521131A5 JP2024521131A5 JP2023572165A JP2023572165A JP2024521131A5 JP 2024521131 A5 JP2024521131 A5 JP 2024521131A5 JP 2023572165 A JP2023572165 A JP 2023572165A JP 2023572165 A JP2023572165 A JP 2023572165A JP 2024521131 A5 JP2024521131 A5 JP 2024521131A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- antibody
- human
- binding
- polypeptide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192549P | 2021-05-24 | 2021-05-24 | |
| US63/192,549 | 2021-05-24 | ||
| US202163265032P | 2021-12-06 | 2021-12-06 | |
| US63/265,032 | 2021-12-06 | ||
| US202263266453P | 2022-01-05 | 2022-01-05 | |
| US63/266,453 | 2022-01-05 | ||
| PCT/US2022/030556 WO2022251119A2 (en) | 2021-05-24 | 2022-05-23 | Engineered polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521131A JP2024521131A (ja) | 2024-05-28 |
| JP2024521131A5 true JP2024521131A5 (https=) | 2025-07-03 |
Family
ID=82156443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572165A Pending JP2024521131A (ja) | 2021-05-24 | 2022-05-23 | 操作されたポリペプチド |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250296986A1 (https=) |
| EP (1) | EP4347642A2 (https=) |
| JP (1) | JP2024521131A (https=) |
| KR (1) | KR20240035758A (https=) |
| AU (1) | AU2022280767A1 (https=) |
| BR (1) | BR112023024494A2 (https=) |
| CA (1) | CA3218489A1 (https=) |
| CL (1) | CL2023003455A1 (https=) |
| CO (1) | CO2023017754A2 (https=) |
| IL (1) | IL308509A (https=) |
| MX (1) | MX2023013859A (https=) |
| TW (1) | TW202306978A (https=) |
| WO (1) | WO2022251119A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022010912A1 (en) | 2020-07-06 | 2022-01-13 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting sars-cov-2 |
| CA3183367A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| CN116528897A (zh) | 2020-08-26 | 2023-08-01 | 旗舰开拓创新六世公司 | 靶向SARS-CoV-2的抗原结合分子 |
| TW202411246A (zh) | 2022-05-23 | 2024-03-16 | 美商維爾生物科技股份有限公司 | 經工程化之b型肝炎病毒中和抗體及其用途 |
| WO2023245078A1 (en) | 2022-06-15 | 2023-12-21 | Humabs Biomed Sa | Anti-parvovirus antibodies and uses thereof |
| WO2024006472A1 (en) | 2022-06-30 | 2024-01-04 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
| CN119836435A (zh) | 2022-07-27 | 2025-04-15 | 胡默波斯生物医学公司 | 抗rsv和mpv副粘病毒的广泛中和抗体 |
| WO2024182781A1 (en) | 2023-03-02 | 2024-09-06 | Vir Biotechnology, Inc. | Coronavirus compositions and uses thereof |
| AU2024255423A1 (en) | 2023-04-10 | 2025-10-30 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
| WO2025010424A1 (en) | 2023-07-06 | 2025-01-09 | Vir Biotechnology, Inc. | Antibodies against staphylococcus antigens and methods of using the same |
| WO2025015321A1 (en) | 2023-07-13 | 2025-01-16 | Vir Biotechnology, Inc. | Broadly neutralizing antibodies against rsv and mpv paramyxoviruses |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2004215125B2 (en) | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| ATE492562T1 (de) | 2003-09-24 | 2011-01-15 | Kyowa Hakko Kirin Co Ltd | Rekombinanter antikörper gegen humanen insulin- like growth factor |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8119772B2 (en) | 2006-09-29 | 2012-02-21 | California Institute Of Technology | MART-1 T cell receptors |
| US20110081347A1 (en) * | 2008-06-04 | 2011-04-07 | Macrogenics, Inc. | Antibodies with Altered Binding to FcRn and Methods of Using Same |
| EP2640745B1 (en) | 2010-09-10 | 2018-11-07 | MedImmune Limited | Bivalent and bispecific anti-il6/anti-il23 antibodies |
| US9663581B2 (en) | 2012-04-25 | 2017-05-30 | Momenta Pharmaceuticals, Inc. | Modified glycoproteins |
| US10519251B2 (en) | 2013-12-30 | 2019-12-31 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| EP3294774B1 (en) | 2015-05-13 | 2024-08-28 | Zumutor Biologics, Inc. | Afucosylated protein, cell expressing said protein and associated methods |
| WO2019024979A1 (en) | 2017-07-31 | 2019-02-07 | Institute For Research In Biomedicine | FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION |
| AU2018334886B2 (en) | 2017-09-22 | 2025-06-26 | WuXi Biologics Ireland Limited | Novel bispecific polypeptide complexes |
| US20220298230A1 (en) * | 2019-06-11 | 2022-09-22 | The Rockefeller University | Antibodies and methods for treatment of viral infections |
-
2022
- 2022-05-23 KR KR1020237044483A patent/KR20240035758A/ko active Pending
- 2022-05-23 MX MX2023013859A patent/MX2023013859A/es unknown
- 2022-05-23 CA CA3218489A patent/CA3218489A1/en active Pending
- 2022-05-23 BR BR112023024494A patent/BR112023024494A2/pt unknown
- 2022-05-23 JP JP2023572165A patent/JP2024521131A/ja active Pending
- 2022-05-23 IL IL308509A patent/IL308509A/en unknown
- 2022-05-23 US US18/563,674 patent/US20250296986A1/en active Pending
- 2022-05-23 TW TW111119113A patent/TW202306978A/zh unknown
- 2022-05-23 AU AU2022280767A patent/AU2022280767A1/en active Pending
- 2022-05-23 WO PCT/US2022/030556 patent/WO2022251119A2/en not_active Ceased
- 2022-05-23 EP EP22732744.2A patent/EP4347642A2/en active Pending
-
2023
- 2023-11-21 CL CL2023003455A patent/CL2023003455A1/es unknown
- 2023-12-19 CO CONC2023/0017754A patent/CO2023017754A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024521131A5 (https=) | ||
| US11377477B2 (en) | PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof | |
| US11505595B2 (en) | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains | |
| US12509495B2 (en) | LAG-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and LAG-3 antigen binding domains | |
| AU2019201923B2 (en) | Heterodimeric antibodies that bind CD3 and tumor antigens | |
| US20240294593A1 (en) | Pd-1 targeted il-15/il-15ralpha fc fusion proteins with improved properties | |
| JP7021127B2 (ja) | ソマトスタチン受容体２に結合するヘテロ二量体抗体 | |
| US12180302B2 (en) | Heterodimeric antibodies that bind fibroblast activation protein | |
| JP7328761B2 (ja) | 多価多重特異性ｏｘ４０結合融合タンパク質 | |
| AU2016262368B2 (en) | Heterodimeric antibodies that bind CD3 and tumor antigens | |
| JP7178342B2 (ja) | アゴニズム及びエフェクター機能が増強した改変抗体、及び他のＦｃドメイン含有分子 | |
| JP7010854B2 (ja) | 二重特異性チェックポイント阻害剤抗体 | |
| JP2019533444A (ja) | ＩＬ−１５／ＩＬ−１５ＲアルファＦｃ融合タンパク質およびＰＤ−１抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質 | |
| US20220227867A1 (en) | ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS | |
| CN119365490A (zh) | 结合pd-l1、pd-l2和/或cd28的抗体 | |
| US20250043001A1 (en) | Anti-cd28 compositions | |
| KR20260035814A (ko) | 직교 다중체 단백질 | |
| US20240392025A1 (en) | B-cell maturation antigen (bcma) binding domain compositions | |
| HK40093127A (zh) | 结合cd3和肿瘤抗原的异二聚体抗体 | |
| HK40065611A (zh) | 结合cd3和肿瘤抗原的异二聚体抗体 | |
| EA044325B1 (ru) | ГЕТЕРОДИМЕРНОЕ АНТИ-CD3xCD20 АНТИТЕЛО, ЕГО ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ |